These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36964936)

  • 1. Nanomedicine for T-Cell Mediated Immunotherapy.
    Li F; Ouyang J; Chen Z; Zhou Z; Milon Essola J; Ali B; Wu X; Zhu M; Guo W; Liang XJ
    Adv Mater; 2024 May; 36(22):e2301770. PubMed ID: 36964936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Engineering Cells for Cancer Immunotherapy.
    Xu X; Li T; Shen S; Wang J; Abdou P; Gu Z; Mo R
    Theranostics; 2019; 9(25):7889-7905. PubMed ID: 31695806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy.
    Lee ES; Shin JM; Son S; Ko H; Um W; Song SH; Lee JA; Park JH
    Adv Healthc Mater; 2019 Feb; 8(4):e1801320. PubMed ID: 30666822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomaterials Enhance Pyroptosis-Based Tumor Immunotherapy.
    Ji F; Shi C; Shu Z; Li Z
    Int J Nanomedicine; 2024; 19():5545-5579. PubMed ID: 38882539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis.
    Zhang P; Zhai Y; Cai Y; Zhao Y; Li Y
    Adv Mater; 2019 Dec; 31(49):e1904156. PubMed ID: 31566275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy.
    Mei Y; Wang R; Jiang W; Bo Y; Zhang T; Yu J; Cheng M; Wu Y; Cheng J; Ma W
    Biomater Sci; 2019 Jun; 7(7):2640-2651. PubMed ID: 31090764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.
    Ji B; Wei M; Yang B
    Theranostics; 2022; 12(1):434-458. PubMed ID: 34987658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.
    Ku KS; Tang J; Chen Y; Shi Y
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications.
    Wu X; Li Y; Wen M; Xie Y; Zeng K; Liu YN; Chen W; Zhao Y
    Chem Soc Rev; 2024 Mar; 53(5):2643-2692. PubMed ID: 38314836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carrier-Free Nanomedicine for Cancer Immunotherapy.
    Fu Y; Bian X; Li P; Huang Y; Li C
    J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives.
    Rehan F; Zhang M; Fang J; Greish K
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer.
    Saeed M; Chen F; Ye J; Shi Y; Lammers T; De Geest BG; Xu ZP; Yu H
    Adv Mater; 2021 Jul; 33(30):e2008094. PubMed ID: 34048101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.
    Lynn GM; Laga R; Jewell CM
    Cancer Lett; 2019 Sep; 459():192-203. PubMed ID: 31185250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy.
    Zhong XF; Sun X
    Acta Pharmacol Sin; 2020 Jul; 41(7):928-935. PubMed ID: 32355277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.
    Elzoghby AO; Ferrone CR; Ferrone S; Nasr ML
    Drug Discov Today; 2023 Jan; 28(1):103434. PubMed ID: 36368630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
    Wei X; Wang J; Liang M; Song M
    Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.